Eurofins Scientific stock
ERF.PAPAREurofins Scientific SE, HealthcareISIN FR0014000MR3
62Score 62 out of 100, Neutral
Price and trend
80 / 100
Price history
+48% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 1.2% below its 52-week high. Largest decline in 20 years: 68% (November 2007 to March 2009).
Chart figures for advanced users
- SMA 50$88.05
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$76.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$62.87
- The lowest closing price of the last twelve months.
- Resistance$98.67
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Eurofins Scientific SE belongs to the Medical (Diagnostics & Research) industry (Luxembourg) and, with a market value of $16.92B, is number 16 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $8.08B (up 5% year on year) and earnings of $526.35M (up 16.9%).
- For fiscal 2026, analysts expect on average revenue of $8.39B (up 3.8%) and adjusted earnings per share of $4.27 (up 32.9%).
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 240 of 702 in Healthcare, median 53.
- The P/E is 30.5 (Medical (Diagnostics & Research) median 33.7, own median of recent years 26.2).
- Our model puts fair value at $105.49, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
- Earnings turn into cashFree cash flow 120% of earnings over the last 12 months.Fundamentals 85
Weaknesses
- High debtDebt 1.5 times equity (latest quarter), Medical (Diagnostics & Research) median 0.48.Stability 57
Its standout strengths are momentum and fundamentals, while capital allocation and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 61 to 62.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $81.15 and expensive above $150.70 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $103.26 (cash-flow model) and $107.72 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.7%. At 9.7% the fair value would be $98.10, at 7.7% it would be $115.73.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 3.4% on the twelve months before. Revenue has grown strongly since 2006, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 12%, operating 11%, net 7%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 23 Jul 2026EPS reported $2.33 (expected $2.12)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 3.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $4.27−3.6%
- Revenue
- $8.39B+0.7%
- Earnings per share
- $4.87−2.5%
- Revenue
- $8.88B+1.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.9%The outlook is not changed and the midterm guidance of 6.5% stays, while Genomics and Agroscience remain weak with no near term pickup expected.
“You know that most of your investor base is focusing into the top line and the midterm guidance, 6.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Eurofins Scientific
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Quest DiagnosticsDGX $28.66B69
- Guardant HealthGH $20.95B45
- Medpace HoldingsMEDP $18.37B82
- RevvityRVTY $17.52B56
- Charles River Laboratories InternationalCRL $16.33B55
- ICON PublicICLR $15.02B62
- bioMérieuxBIM.PA $12.04B70
- WuXi XDC Cayman2268.HK $11.58B74
ETFs that hold Eurofins Scientific
Held by 110 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.84% | 0.49% | €318.64M |
| Rize Sustainable Future of Food UCITS ETFRIZF | 1.59% | 0.45% | €58.13M |
| iShares EURO STOXX Mid UCITS ETFIQQM | 1.20% | 0.40% | €560.15M |
Show 5 more
| iShares MSCI EMU Mid Cap UCITS ETF EURIS3H | 0.82% | 0.49% | €570.32M |
| Amundi MSCI EMU SRI Climate Paris Aligned UCITS ETF DR (C)SRHE | 0.74% | 0.18% | €121.19M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.62% | 0.25% | €36.34M |
| iShares STOXX Europe Mid 200 UCITS ETF (DE)EXSD | 0.59% | 0.20% | €634.13M |
| Xtrackers CAC 40 UCITS ETF 1DDX2G | 0.56% | 0.20% | €129.36M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.